The roles and regulation of MDM2 and MDMX: it is not just about p53

Small‐molecule MDM2 inhibitor LQFM030‐induced apoptosis in p53‐null K562 chronic myeloid leukemia cells

(2020) Higor de Oliveira Ribeiro et al.   FUNDAMENTAL & CLINICAL PHARMACOLOGY

MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling

(2020) Divya Venkatesh et al.   GENES & DEVELOPMENT

Long non‐coding RNA XIST expedites lung adenocarcinoma progression through upregulating MDM2 expression via binding to miR‐363‐3p

(2020) Hao Rong et al.   Thoracic Cancer

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

(2020) Yuan Fang et al.   Acta Pharmaceutica Sinica B

Mdm2 – open questions

(2020) Matthias Dobbelstein et al.   CANCER SCIENCE

Genome-wide association study identifies zonisamide responsive gene in Parkinson’s disease patients

(2020) Pei-Chieng Cha et al.   JOURNAL OF HUMAN GENETICS

CircularRNA-9119 promotes the proliferation of cervical cancer cells by sponging miR-126/MDM4

(2020) Yonghui Tian et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Mdm4 supports DNA replication in a p53-independent fashion

(2020) Kai Wohlberedt et al.   ONCOGENE

SIRT7 activates p53 by enhancing PCAF-mediated MDM2 degradation to arrest the cell cycle

(2020) Ya-Fei Lu et al.   ONCOGENE

The p53/MDM2/MDMX-targeted therapies—a clinical synopsis

(2020) Liren Jiang et al.   Cell Death & Disease

Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain

(2020) Helge M. Magnussen et al.   Nature Communications

MDM2-Mediated Ubiquitination of ACE2 Contributes to the Development of Pulmonary Arterial Hypertension

(2020) Hui Shen et al.   CIRCULATION

Downregulation of miR-194-5p induces paclitaxel resistance in ovarian cancer cells by altering MDM2 expression

(2019) Koji Nakamura et al.   Oncotarget

Evidence for an Integrated Gene Repression Mechanism Based on mRNA Isoform Toggling in Human Cells

(2019) Ina Hollerer et al.   G3-Genes Genomes Genetics

DBC1 Regulates p53 Stability via Inhibition of CBP-Dependent p53 Polyubiquitination

(2019) Oluwatoyin E. Akande et al.   Cell Reports

miRNA‑766 induces apoptosis of human colon cancer cells through the p53/Bax signaling pathway by MDM4

(2019) Weirong Chen et al.   Experimental and Therapeutic Medicine

MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1

(2019) Zhengyi Cao et al.   ONCOGENE

MDM2 Integrates Cellular Respiration and Apoptotic Signaling through NDUFS1 and the Mitochondrial Network

(2019) Rana Elkholi et al.   MOLECULAR CELL

Mdm2 is required for HDAC3 monoubiquitination and stability

(2019) Yeong Min Choi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Oncogenic effect of PHLDB2 is associated with epithelial–mesenchymal transition and E-cadherin regulation in colorectal cancer

(2019) Geng Chen et al.   Cancer Cell International

miR-33a inhibits cell growth in renal cancer by downregulation of MDM4 expression

(2019) Kehua Jiang et al.   Molecular Genetics & Genomic Medicine

CircSAMD4A accelerates cell proliferation of osteosarcoma by sponging miR-1244 and regulating MDM2 mRNA expression

(2019) Zhao Yanbin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

MDM2-NFAT1 dual inhibitor, MA242: Effective against hepatocellular carcinoma, independent of p53

(2019) Wei Wang et al.   CANCER LETTERS

Targeting MDM2 for novel molecular therapy: Beyond oncology

(2019) Wei Wang et al.   MEDICINAL RESEARCH REVIEWS

SRSF2 Regulation of MDM2 Reveals Splicing as a Therapeutic Vulnerability of the p53 Pathway

(2019) Daniel F. Comiskey et al.   MOLECULAR CANCER RESEARCH

miR-1305 Inhibits The Progression Of Non-Small Cell Lung Cancer By Regulating MDM2

(2019) Yuxing Cai et al.   Cancer Management and Research

Mdm2 is a target and mediator of IRP2 in cell growth control

(2019) Jin Zhang et al.   FASEB JOURNAL

Inhibition of Noncanonical Mouse Double Minute 2 Homolog Abrogates Ocular Inflammation through NF-κB Suppression

(2018) Yan Fan et al.   AMERICAN JOURNAL OF PATHOLOGY

Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner

(2018) Oleg Shuvalov et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling

(2018) Debanjan Dhar et al.   CANCER CELL

Peli1 Modulates the Subcellular Localization and Activity of Mdmx

(2018) Dawei Li et al.   CANCER RESEARCH

Regulation of the Mdm2–p53 pathway by the ubiquitin E3 ligase MARCH7

(2018) Kailiang Zhao et al.   EMBO REPORTS

Dysregulation of Mdm2 and Mdm4 alternative splicing underlies motor neuron death in spinal muscular atrophy

(2018) Meaghan Van Alstyne et al.   GENES & DEVELOPMENT

Suppression of IKK, but not activation of p53 is responsible for cell death mediated by naturally occurring oxidized tetranortriterpenoid

(2018) Pankaj Gupta et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

LQFM030 reduced Ehrlich ascites tumor cell proliferation and VEGF levels

(2018) Mariana Flavia da Mota et al.   LIFE SCIENCES

Mitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53

(2018) Giuseppe Arena et al.   MOLECULAR CELL

Inhibition of Mdmx (Mdm4) in vivo induces anti-obesity effects

(2018) Ning Kon et al.   Oncotarget

Influenza A viruses alter the stability and antiviral contribution of host E3-ubiquitin ligase Mdm2 during the time-course of infection

(2018) Andrés Pizzorno et al.   Scientific Reports

MDM4 contributes to the increased risk of glioma susceptibility in Han Chinese population

(2018) Peng Sun et al.   Scientific Reports

Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53

(2018) Xinyan Wang et al.   Thoracic Cancer

Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype

(2018) Daniel J. McGrail et al.   Cell Reports

Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy

(2018) Jiang-Jiang Qin et al.   Frontiers in Pharmacology

The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways

(2018) Hang Li et al.   ACTA PHARMACOLOGICA SINICA

The Dysfunctional MDM2-p53 Axis in Adipocytes Contributes to Ageing Related Metabolic Complications by Induction of Lipodystrophy

(2018) Zhuohao Liu et al.   DIABETES

OUP accepted manuscript

(2018)   TOXICOLOGICAL SCIENCES

MDM2 and Mitochondrial Function: One Complex Intersection

(2018) Camila Rubio-Patiño et al.   BIOCHEMICAL PHARMACOLOGY

Downregulation of microRNA‐23b protects against ischemia‐reperfusion injury via p53 signaling pathway by upregulating MDM4 in rats

(2018) Zhi Zhao et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Circular RNA hsa_circ_0000263 participates in cervical cancer development by regulating target gene of miR-150-5p

(2018) Hongning Cai et al.   JOURNAL OF CELLULAR PHYSIOLOGY

MDM2-mediated degradation of WRN promotes cellular senescence in a p53-independent manner

(2018) Boya Liu et al.   ONCOGENE

Chromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication

(2018) Ina Klusmann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Distinct control of PERIOD2 degradation and circadian rhythms by the oncoprotein and ubiquitin ligase MDM2

(2018) JingJing Liu et al.   Science Signaling

Dysfunction of the MDM2/p53 axis is linked to premature aging

(2017) Davor Lessel et al.   JOURNAL OF CLINICAL INVESTIGATION

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer

(2017) Veronica Tisato et al.   Journal of Hematology & Oncology

The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis

(2017) Shunbin Xiong et al.   JOURNAL OF PATHOLOGY

HDM2 Promotes NEDDylation of Hepatitis B Virus HBx To Enhance Its Stability and Function

(2017) Ningning Liu et al.   JOURNAL OF VIROLOGY

MDM4 actively restrains cytoplasmic mTORC1 by sensing nutrient availability

(2017) Francesca Mancini et al.   Molecular Cancer

Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice

(2017) Lubing Gu et al.   MOLECULAR CANCER THERAPEUTICS

Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase

(2017) L E Giono et al.   ONCOGENE

Mdm2 selectively suppresses DNA damage arising from inhibition of topoisomerase II independent of p53

(2017) J C Senturk et al.   ONCOGENE

Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function

(2017) Naoe T. Nihira et al.   Science Signaling

Mouse modeling of the MDM2/MDMX−p53 signaling axis

(2017) Nicole R. Tackmann et al.   Journal of Molecular Cell Biology

MBD2 upregulates miR-301a-5p to induce kidney cell apoptosis during vancomycin-induced AKI

(2017) Juan Wang et al.   Cell Death & Disease

Hepatitis B virus X protein promotes the stem-like properties of OV6+ cancer cells in hepatocellular carcinoma

(2017) Chao Wang et al.   Cell Death & Disease

MiR‑370 promotes apoptosis in colon cancer by directly targeting MDM4

(2017) Xiaogang Shen et al.   Oncology Letters

The fate of murine double minute X (MdmX) is dictated by distinct signaling pathways through murine double minute 2 (Mdm2)

(2017) Paula M. Hauck et al.   Oncotarget

BTK blocks the inhibitory effects of MDM2 on p53 activity

(2017) Miran Rada et al.   Oncotarget

MDM4 genetic variants and risk of gastric cancer in an Eastern Chinese population

(2017) Meng-Yun Wang et al.   Oncotarget

MiR-766 induces p53 accumulation and G2/M arrest by directly targeting MDM4

(2017) Qingqing Wang et al.   Oncotarget

Tumorigenesis promotes Mdm4-S overexpression

(2017) Vinod Pant et al.   Oncotarget

Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway

(2017) Nandini Kundu et al.   Oncotarget

NFkB is essential for activin-induced colorectal cancer migration via upregulation of PI3K-MDM2 pathway

(2017) Arundhati Jana et al.   Oncotarget

Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function

(2017) Naoe T. Nihira et al.   Science Signaling

Identification of XBP1-u as a novel regulator of the MDM2/p53 axis using an shRNA library

(2017) Can Huang et al.   Science Advances

Profile of the breast cancer susceptibility marker rs4245739 identifies a role for miRNAs

(2017) Lukman Anwar Sumadi et al.   Cancer Biology & Medicine

MDM2 Contributes to High Glucose-Induced Glomerular Mesangial Cell Proliferation and Extracellular Matrix Accumulation via Notch1

(2017) Chun-Tao Lei et al.   Scientific Reports

Murine Double Minute-2 Inhibition Ameliorates Established Crescentic Glomerulonephritis

(2016) Shrikant R. Mulay et al.   AMERICAN JOURNAL OF PATHOLOGY

The Roles of MDM2 and MDMX in Cancer

(2016) Orit Karni-Schmidt et al.   Annual Review of Pathology-Mechanisms of Disease

RNF12 promotes p53-dependent cell growth suppression and apoptosis by targeting MDM2 for destruction

(2016) Kun Gao et al.   CANCER LETTERS

2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway

(2016) Jingwen Xu et al.   CANCER LETTERS

Dual targeting of MDM2 with a novel small-molecule inhibitor overcomes TRAIL resistance in cancer

(2016) Anup Kumar Singh et al.   CARCINOGENESIS

PPARγ neddylation essential for adipogenesis is a potential target for treating obesity

(2016) H-S Park et al.   CELL DEATH AND DIFFERENTIATION

Analysis of the Association between MDM4 rs4245739 Single Nucleotide Polymorphism and Breast Cancer Susceptibility

(2016) Negar Pedram et al.   Clinical Laboratory

MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53

(2016) Weichao Sun et al.   CURRENT MEDICINAL CHEMISTRY

NAT10 regulates p53 activation through acetylating p53 at K120 and ubiquitinating Mdm2

(2016) Xiaofeng Liu et al.   EMBO REPORTS

Changes inO-LinkedN-Acetylglucosamine (O-GlcNAc) Homeostasis Activate the p53 Pathway in Ovarian Cancer Cells

(2016) Rafaela Muniz de Queiroz et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Induction of apoptosis in Ehrlich ascites tumour cells via p53 activation by a novel small-molecule MDM2 inhibitor - LQFM030

(2016) Mariana F. da Mota et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53

(2016) Magdalena Wienken et al.   MOLECULAR CELL

Chromatin-Bound MDM2 Regulates Serine Metabolism and Redox Homeostasis Independently of p53

(2016) Romain Riscal et al.   MOLECULAR CELL

FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2

(2016) T Liu et al.   ONCOGENE

MDM2 oligomers: antagonizers of the guardian of the genome

(2016) P L Leslie et al.   ONCOGENE

MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation

(2016) D-L Qi et al.   ONCOGENE

Macrophage migration inhibitory factor induces phosphorylation of Mdm2 mediated by phosphatidylinositol 3-kinase/Akt kinase: Role of this pathway in decidual cell survival

(2016) Adriana Fraga Costa et al.   PLACENTA

The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer

(2016) Liv B. Gansmo et al.   TUMOR BIOLOGY

AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX–MDM2 complex

(2016) Anna de Polo et al.   Journal of Molecular Cell Biology

Mdm2 as a chromatin modifier

(2016) Magdalena Wienken et al.   Journal of Molecular Cell Biology

Role of Mdm2 and Mdmx in DNA repair

(2016) Christine M. Eischen   Journal of Molecular Cell Biology

MDM2 facilitates adipocyte differentiation through CRTC-mediated activation of STAT3

(2016) P Hallenborg et al.   Cell Death & Disease

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

(2016) Liv B. Gansmo et al.   Oncotarget

microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis

(2016) Cen Zhang et al.   Oncotarget

Ribosomal protein L4 is a novel regulator of the MDM2-p53 loop

(2016) Xia He et al.   Oncotarget

USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation

(2016) Sathish Kumar Mungamuri et al.   Cell Reports

The Evolution of the Ribosomal Protein–MDM2–p53 Pathway

(2016) Chad Deisenroth et al.   Cold Spring Harbor Perspectives in Medicine

The Role of MDM2 Amplification and Overexpression in Tumorigenesis

(2016) Jonathan D. Oliner et al.   Cold Spring Harbor Perspectives in Medicine

The Zn-finger domain of MdmX suppresses cancer progression by promoting genome stability in p53-mutant cells

(2016) Z Matijasevic et al.   Oncogenesis

Regulation of the Mdm2-p53 signaling axis in the DNA damage response and tumorigenesis

(2016) Michael I. Carr et al.   Translational Cancer Research

Clinical Overview of MDM2/X-Targeted Therapies

(2016) Andrew Burgess et al.   Frontiers in Oncology

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer

(2016) Reham Helwa et al.   Scientific Reports

SNP55, a new functional polymorphism of MDM2-P2 promoter, contributes to allele-specific expression of MDM2 in endometrial cancers

(2015) Kanako Okamoto et al.   BMC Medical Genetics

Interaction between p53 Mutation and a Somatic HDMX Biomarker Better Defines Metastatic Potential in Breast Cancer

(2015) A. M. Grawenda et al.   CANCER RESEARCH

WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma

(2015) Y. Sun et al.   CANCER RESEARCH

Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia

(2015) M. Andreeff et al.   CLINICAL CANCER RESEARCH

A genetic variant of MDM4 influences regulation by multiple microRNAs in prostate cancer

(2015) S. Stegeman et al.   ENDOCRINE-RELATED CANCER

The MDM2 RING Domain and Central Acidic Domain Play Distinct Roles in MDM2 Protein Homodimerization and MDM2-MDMX Protein Heterodimerization

(2015) Patrick L. Leslie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Regulation of MDM2 Stability After DNA Damage

(2015) Jiaqi Li et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Antisense oligonucleotide–mediated MDM4 exon 6 skipping impairs tumor growth

(2015) Michael Dewaele et al.   JOURNAL OF CLINICAL INVESTIGATION

Hyperglycemia promotes p53-Mdm2 interaction but reduces p53 ubiquitination in RINm5F cells

(2015) Barzalobre-Gerónimo Raúl et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

Inhibition of MDM2 homodimerization by XIAP IRES stabilizes MDM2, influencing cancer cell survival

(2015) Tao Liu et al.   Molecular Cancer

Requirement for human Mps1/TTK in oxidative DNA damage repair and cell survival through MDM2 phosphorylation

(2015) Zheng-Cheng Yu et al.   NUCLEIC ACIDS RESEARCH

Splicing factor SRSF1 negatively regulates alternative splicing of MDM2 under damage

(2015) Daniel F. Comiskey et al.   NUCLEIC ACIDS RESEARCH

A Regulatory MDM4 Genetic Variant Locating in the Binding Sequence of Multiple MicroRNAs Contributes to Susceptibility of Small Cell Lung Cancer

(2015) Feng Gao et al.   PLoS One

Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylating E3 ligase

(2015) Christopher N. Batuello et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting RING domains of Mdm2–MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells

(2015) W Wu et al.   Cell Death & Disease

XI-006 induces potent p53-independent apoptosis in Ewing sarcoma

(2015) Kathleen I. Pishas et al.   Scientific Reports

Regulation of Mutant p53 Protein Expression

(2015) Reshma Vijayakumaran et al.   Frontiers in Oncology

A Small-Molecule p53 Activator Induces Apoptosis through Inhibiting MDMX Expression in Breast Cancer Cells

(2015) Hongbo Wang et al.   NEOPLASIA

p53-Independent Roles of MDM2 in NF-κB Signaling: Implications for Cancer Therapy, Wound Healing, and Autoimmune Diseases

(2015) Dana Thomasova et al.   NEOPLASIA

The regulation of MDM2 oncogene and its impact on human cancers

(2014) Y. Zhao et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

(2014) Patricia A.J. Muller et al.   CANCER CELL

FL118 Induces p53-Dependent Senescence in Colorectal Cancer Cells by Promoting Degradation of MdmX

(2014) X. Ling et al.   CANCER RESEARCH

The anaphase-promoting complex/cyclosome is an E3 ubiquitin ligase for Mdm2

(2014) Yizhou He et al.   CELL CYCLE

Identification of a New Class of MDM2 Inhibitor That Inhibits Growth of Orthotopic Pancreatic Tumors in Mice

(2014) Wei Wang et al.   GASTROENTEROLOGY

The Splicing Factor FUBP1 Is Required for the Efficient Splicing of OncogeneMDM2Pre-mRNA

(2014) Aishwarya G. Jacob et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mdmx promotes genomic instability independent of p53 and Mdm2

(2014) A M Carrillo et al.   ONCOGENE

Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase

(2014) C Xu et al.   ONCOGENE

Inhibition of MDM2 by Nilotinib Contributes to Cytotoxicity in Both Philadelphia-Positive and Negative Acute Lymphoblastic Leukemia

(2014) Hailong Zhang et al.   PLoS One

The pyrido[b]indole MDM2 inhibitor SP-141 exerts potent therapeutic effects in breast cancer models

(2014) Wei Wang et al.   Nature Communications

Non-degradative ubiquitination of the Notch1 receptor by the E3 ligase MDM2 activates the Notch signalling pathway

(2013) Susanne Pettersson et al.   BIOCHEMICAL JOURNAL

Regulation of constitutive and alternative splicing by PRMT5 reveals a role for Mdm4 pre-mRNA in sensing defects in the spliceosomal machinery

(2013) M. Bezzi et al.   GENES & DEVELOPMENT

MDM2’s social network

(2013) R Fåhraeus et al.   ONCOGENE

A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53

(2013) M. Kurokawa et al.   Science Signaling

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

(2013) Binh Vu et al.   ACS Medicinal Chemistry Letters

Spliced MDM2 isoforms promote mutant p53 accumulation and gain-of-function in tumorigenesis

(2013) Tongsen Zheng et al.   Nature Communications

Alternate Splicing of the p53 Inhibitor HDMX Offers a Superior Prognostic Biomarker than p53 Mutation in Human Cancer

(2012) Kristiaan Lenos et al.   CANCER RESEARCH

S-MDM4 mRNA overexpression indicates a poor prognosis and marks a potential therapeutic target in chronic lymphocytic leukemia

(2012) Ling Liu et al.   CANCER SCIENCE

Mutational analysis of Mdm2 C-terminal tail suggests an evolutionarily conserved role of its length in Mdm2 activity toward p53 and indicates structural differences between Mdm2 homodimers and Mdm2/MdmX heterodimers

(2012) Pavlina Dolezelova et al.   CELL CYCLE

Natural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action

(2012) J.-J. Qin et al.   CURRENT MEDICINAL CHEMISTRY

A 40-bp insertion/deletion polymorphism in the constitutive promoter of MDM2 confers risk for hepatocellular carcinoma in a Chinese population

(2012) Dong Dong et al.   GENE

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

Integration of DNA Damage and Repair with Murine Double-Minute 2 (Mdm2) in Tumorigenesis

(2012) Jason Lehman et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Transcription Factor NFAT1 Activates themdm2Oncogene Independent of p53

(2012) Xu Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

MDM2 (murine double minute-2) links inflammation and tubular cell healing during acute kidney injury in mice

(2012) Shrikant R. Mulay et al.   KIDNEY INTERNATIONAL

MDM2 expression is repressed by the RNA-binding protein RNPC1 via mRNA stability

(2012) E Xu et al.   ONCOGENE

MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk

(2012) Stian Knappskog et al.   PLoS One

Preclinical assessment of JNJ-26854165 (Serdemetan), a novel tryptamine compound with radiosensitizing activity in vitro and in tumor xenografts

(2011) Cyrus Chargari et al.   CANCER LETTERS

MDM2 promotes SUMO-2/3 modification of p53 to modulate transcriptional activity

(2011) Maren H. Stindt et al.   CELL CYCLE

UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53

(2011) Hong Wu et al.   NATURE MEDICINE

The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo

(2011) L. Huang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors

(2011) A V Vaseva et al.   Cell Death & Disease

Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay

(2011) A. G. Herman et al.   Cancer Discovery

Phosphorylation by Casein Kinase I Promotes the Turnover of the Mdm2 Oncoprotein via the SCFβ-TRCP Ubiquitin Ligase

(2010) Hiroyuki Inuzuka et al.   CANCER CELL

A High-Frequency Regulatory Polymorphism in the p53 Pathway Accelerates Tumor Development

(2010) Sean M. Post et al.   CANCER CELL

Specific inhibition of Mdm2-mediated neddylation by Tip60

(2010) Christoph Dohmesen et al.   CELL CYCLE

Single-Nucleotide Polymorphisms in p53 Pathway and Aggressiveness of Prostate Cancer in a Caucasian Population

(2010) T. Sun et al.   CLINICAL CANCER RESEARCH

Regulation of MDM4

(2010) Michael et al.   Frontiers in Bioscience-Landmark

The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor

(2010) J. J. Manfredi   GENES & DEVELOPMENT

HDMX-L Is Expressed from a Functional p53-responsive Promoter in the First Intron of theHDMXGene and Participates in an Autoregulatory Feedback Loop to Control p53 Activity

(2010) Anna Phillips et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Turning the RING Domain Protein MdmX into an Active Ubiquitin-Protein Ligase

(2010) Saravanakumar Iyappan et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis

(2010) H. Wang et al.   MOLECULAR CANCER THERAPEUTICS

NF- B inhibits T-cell activation-induced, p73-dependent cell death by induction of MDM2

(2010) V. Busuttil et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The p53 orchestra: Mdm2 and Mdmx set the tone

(2010) Mark Wade et al.   TRENDS IN CELL BIOLOGY

Signaling to p53: Ribosomal Proteins Find Their Way

(2009) Yanping Zhang et al.   CANCER CELL

Rapamycin increases the p53/MDM2 protein ratio and p53-dependent apoptosis by translational inhibition of mdm2 in cancer cells

(2009) Chia-Li Kao et al.   CANCER LETTERS

Mdm2-mediated ubiquitylation: p53 and beyond

(2009) J-C Marine et al.   CELL DEATH AND DIFFERENTIATION

MDM4 (MDMX) and its Transcript Variants

(2009) F. Mancini et al.   CURRENT GENOMICS

Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase

(2009) Koji Okamoto et al.   FEBS LETTERS

Regulation of Expression of the Rat Orthologue of Mouse Double Minute 2 (MDM2) by H2O2-induced Oxidative Stress in Neonatal Rat Cardiac Myocytes

(2009) Sampsa Pikkarainen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

IFN Regulatory Factor 8 Regulates MDM2 in Germinal Center B Cells

(2009) J. X. Zhou et al.   JOURNAL OF IMMUNOLOGY

ELF4/MEF Activates MDM2 Expression and Blocks Oncogene-Induced p16 Activation To Promote Transformation

(2009) G. Sashida et al.   MOLECULAR AND CELLULAR BIOLOGY

Chemotherapy induces NEDP1-mediated destabilization of MDM2

(2009) I R Watson et al.   ONCOGENE

CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53

(2009) D. Shi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The regulation of MDM2 by multisite phosphorylation—Opportunities for molecular-based intervention to target tumours?

(2009) David W. Meek et al.   SEMINARS IN CANCER BIOLOGY

TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use

(2009) M. Olivier et al.   Cold Spring Harbor Perspectives in Biology

Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans

(2008) K Linke et al.   CELL DEATH AND DIFFERENTIATION

Regulation of MDMX Expression by Mitogenic Signaling

(2008) D. M. Gilkes et al.   MOLECULAR AND CELLULAR BIOLOGY

Mdm2 and Mdm4 Loss Regulates Distinct p53 Activities

(2008) J. A. Barboza et al.   MOLECULAR CANCER RESEARCH

Targeting tumor cells expressing p53 with a water-soluble inhibitor of Hdm2

(2008) J. Kitagaki et al.   MOLECULAR CANCER THERAPEUTICS

Regulation of Peroxisome Proliferator–Activated Receptor-α by MDM2

(2008) Lakshmi Gopinathan et al.   TOXICOLOGICAL SCIENCES

Peroxisome Proliferator Activated Receptors and Lipoprotein Metabolism

(2007) Sander Kersten   PPAR Research